Product Name: Ibrutinib
 CAT#: A-1383

Request Ibrutinib
 Synonym: Ibrutinib,PCI-32765

Ibrutinib Chemical Structure
Ibrutinib chemical structure


5 stars, based on 879461 reviews
$1 Order now!
IUPAC/Chemical name:

Price of Ibrutinib

We offer a substantial discount on larger orders,
please inquire via sales@activebiochem.com
or Fax: 1-201-884-1288 (USA Fax#)


Biological Activity
Ibrutinib, also known as PCI-32765, is a BTK inhibitor, is also an orally bioavailable small-molecule inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity. BTK inhibitor PCI-32765 binds to and inhibits BTK activity, preventing B-cell activation and B-cell-mediated signaling and inhibiting the growth of malignant B cells that overexpress BTK. BTK, a member of the src-related BTK/Tec family of cytoplasmic tyrosine kinases, is required for B cell receptor (BCR) signaling, plays a key role in B-cell maturation, and is overexpressed in a number of B-cell malignancies. Ibrutinib was approved by the US FDA on November 13, 2013 for the treatment of mantle cell lymphoma.
Ibrutinib shows the potent and irreversible inhibitory effect and selectivity for Btk enzymatic activity. In BCR pathway-activated DOHH2 cell line, Ibrutinib inhibits autophosphorylation of Btk, phosphorylation of Btk's physiological substrate PLCγ, and phosphorylation of further downstream kinase, ERK with IC50 of 11 nM, 29 nM and 13 nM, respectively. Ibrutinib exhibits a significant dose-dependent and time-dependent induction of cytotoxicity in chronic lymphocytic leukemia (CLL) cells. In addition, Ibrutinib induces cell death depending on caspase pathway activation and antagonizes the ability of CLL cells to proliferate after TLR signaling. A recent study shows that Ibrutinib inhibits BCR-activated primary B cell proliferation with IC50 of 8 nM and results in inhibition of TNFα, IL-1β and IL-6 production in primary monocytes with IC50 of 2.6 nM, 0.5 nM and 3.9 nM, respectively.
In a collagen-induced arthritis model, Ibrutinib significantly reduces clinical arthritis scores reflecting paw swelling and joint inflammation by inhibiting B-cell activation. In a MRL-Fas(lpr) lupus model, Ibrutinib reduces renal disease and autoantibody production. In an adoptive transfer TCL1 mouse model of CLL, Ibrutinib (25 mg/kg/day) causes a transient early lymphocytosis, and delays CLL disease progression.
Technical Data

Formula:C25H24N6O2
CAS#: 936563-96-1
M.Wt:440.5
Solubility:Soluble in DMSO
Purity: >99%
Storage Conditions: Room temperature, or -20ºC for 3 years.

Reference







Purchase(buy) Ibrutinib at Active Biochem and the United State(U.S.), Germany, Japan, France,United Kingdom(UK),Switzerland, Australia distributors.